Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0081312 |
| Name | T-cell non-Hodgkin lymphoma |
| Definition | A non-Hodgkin lymphoma of T-cell lineage. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma T-cell non-Hodgkin lymphoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05110742 | Phase Ib/II | CAR.5/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine | Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances | Active, not recruiting | USA | 0 |
| NCT05313243 | Phase II | Brentuximab vedotin + Pembrolizumab | Pembrolizumab and Brentuximab Vedotin in Subjects with Relapsed/Refractory T-cell Lymphoma | Recruiting | USA | 0 |
| NCT05627245 | Phase I | Belinostat + Tazemetostat | Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment | Recruiting | USA | 0 |
| NCT05996185 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Mogamulizumab + Prednisone + Vincristine Sulfate | Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma | Recruiting | USA | 0 |
| NCT06018129 | Phase Ib/II | GEN3017 | A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma | Terminated | USA | AUS | 0 |
| NCT06420089 | Phase I | Cyclophosphamide + Fludarabine + Senza5 CART5 Senza5 CART5 | CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL) (VIPER101) | Recruiting | USA | 0 |
| NCT06492304 | Phase Ib/II | CTX131 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | Recruiting | USA | AUS | 0 |
| NCT06522737 | Phase III | Duvelisib Gemcitabine Bendamustine | A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype (TERZO) | Recruiting | POL | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CZE | 0 |